Novartis on track to to produce 90 million units of Influenza A (H1N1) vaccine for the US, Novartis International AG

Release Date: 2009-10-29

Basel, October 29, 2009 - Novartis confirmed today that it has shipped over 7.5 million doses of Influenza A(H1N1)[1] vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in pre-filled syringes and multi-dose vials by the end of November. 90 million units of bulk antigen expected to result in 60 million vaccine doses due to required overage and overfills in the filling process of multi-dose vials and pre-filled syringes.
Smaller changes in delivery timelines and volumes can result out of the variability of the underlying biological production process. The deliveries are in line with commitments made to the US Department of Health and Human Services (HHS).

In addition, the company is progressing with the production of its proprietary adjuvant MF59(TM) for the US. Adjuvants have shown to be antigen sparing and can double the number of vaccine doses produced. To date, Novartis has shipped more than 7.5 million doses of Influenza A (H1N1) vaccines in multi-dose vials and pre-filled syringes ready to use, and expects to reach 25 to 30 million doses by the end of November. Novartis also initiated deliveries against the 90 million doses of proprietary adjuvant, which could be used to double the amount of vaccine doses produced.

"Overall, we are pleased with the progress achieved to date, given the many challenges and uncertainties of the current pandemic. Not only did we complete our commitment to provide seasonal vaccine ahead of schedule, we are making every effort to make as much H1N1 vaccine available as quickly as possible," said Andrin Oswald, CEO of Novartis Vaccines and Diagnostics. "However, we acknowledge the limitations of the old manufacturing sites and technologies for influenza vaccines to rapidly respond to the needs of a pandemic. Over the last three years, Novartis has made major R&D investments to develop new technologies. And in partnership with HHS, we are building the first cell based flu manufacturing facility in the US. The opening of the site is planned later this year."
Type: NORMAL
Company: Novartis International AG
Country: Switzerland
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.